Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.
Recruiting
Observational Study
Vulvo-vaginal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Female
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Tata Memorial Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The vaginal cancers are responsible for 2% of gynecological cancer while vulvar cancers account for 4 % of gynecological cancers. HPV 16 and 33 are most prevalent in vaginal cancers and account for more than half of cases HPV related vaginal cancer. However, adeqaute information is not there. Similarly, structured QOL data is not available for India. Therefore, in the proposed study we will like t…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. All patients diagnosed with vulvo- vaginal cancer.
2. Patients treated with Radiation+/- chemotherapy+/-surgery from January 1, 2019- December 31, 2023.
Exclusion Criteria:
1. Patients with Metastatic disease at the presentation.
2. Incomplete information on the EMR.
Contacts